CFO
PROK icon

Callan Family Office’s ProKidney PROK Stock Holding History

Callan Family Office’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24K Hold
13,394
– – ﹤0.01% 1123
2025
Q4 		$30K Buy
+13,394
New +$35.2K ﹤0.01% 1103

Other funds holding PROK

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Callan Family Office's PROK Position: Q1 2026 in Review

Callan Family Office held its ProKidney (PROK) position steady in Q1 2026 at 13,394 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #1123.

Callan Family Office first reported a position in PROK in Q4 2025 and has held it in 2 quarters since. The position peaked at $30K in Q4 2025. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

  • Callan Family Office held 13,394 shares of ProKidney worth $24K as of Q1 2026.
  • Callan Family Office left its ProKidney share count unchanged in Q1 2026.
  • ProKidney made up ﹤0.01% of Callan Family Office's portfolio in Q1 2026, its #1123 holding.
  • Callan Family Office first reported a position in ProKidney in Q4 2025 and has held it in 2 quarters since.
  • Callan Family Office's ProKidney position peaked at $30K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.